MedTrace Logo

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2026-02-12

No results posted yet for this study

Summary

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

BIOLOGICAL

Tibulizumab Dose A

Anti BAFF/IL-17 antibody. ZB-106

BIOLOGICAL

Tibulizumab Dose B

Anti BAFF/IL-17 antibody. ZB-106

OTHER

Placebo

ZB-106 Placebo

Sponsors & Collaborators

  • Zura Bio Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-16
Primary Completion
2026-11-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993610 on ClinicalTrials.gov